These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 3325574)

  • 41. Combined clofazimine- and dapsone-resistant leprosy. A case report.
    Kar HK; Bhatia VN; Harikrishnan S
    Int J Lepr Other Mycobact Dis; 1986 Sep; 54(3):389-91. PubMed ID: 3528345
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
    Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
    Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Single-dose treatment for paucibacillary leprosy; clinical problems and management.
    Pai VV; Bulchand HO; Revankar CR; Ganapati R
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):310-2. PubMed ID: 10575414
    [No Abstract]   [Full Text] [Related]  

  • 44. Susceptibility of strains of Mycobacterium leprae isolated prior to 1977 from patients with previously untreated lepromatous leprosy.
    Shepard CC; Rees RJ; Levy L; Pattyn SR; Baohong J; Dela Cruz EC
    Int J Lepr Other Mycobact Dis; 1986 Mar; 54(1):11-5. PubMed ID: 3519796
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Are viable Mycobacterium leprae present in lepromatous patients after completion of 12 months' and 24 months' multi-drug therapy?
    Ebenezer GJ; Daniel S; Norman G; Daniel E; Job CK
    Indian J Lepr; 2004; 76(3):199-206. PubMed ID: 15835604
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Treatment of lepromatous Hansen disease with a rifampicine-isoprodian association (author's transl)].
    Colin M; de Montaigne E
    Med Trop (Mars); 1980; 40(2):157-9. PubMed ID: 6991851
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rifampicin resistant leprosy: a review and a research proposal of a pilot study.
    Ji B
    Lepr Rev; 2002 Mar; 73(1):2-8. PubMed ID: 11969122
    [No Abstract]   [Full Text] [Related]  

  • 48. In vivo antileprosy activity of the newly synthesized benzoxazinorifamycin, KRM-1648.
    Tomioka H; Saito H
    Int J Lepr Other Mycobact Dis; 1993 Jun; 61(2):255-8. PubMed ID: 8371034
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Antibacterial chemotherapy in leprosy: principles, objectives and recommendations].
    Sansarricq H
    Acta Leprol; 1986; 4(3):355-62. PubMed ID: 3551474
    [No Abstract]   [Full Text] [Related]  

  • 50. Recent trends in chemotherapy of leprosy.
    Parikh DA; Maniar JK; Parikh AC; Ganapati R
    J Assoc Physicians India; 1985 Sep; 33(9):593-5. PubMed ID: 3912375
    [No Abstract]   [Full Text] [Related]  

  • 51. Secondary sulphone resistance in leprosy (Report of a case).
    Lal S; Jaganath C; Garg BR; Paneerselvam R
    Lepr India; 1980 Apr; 52(2):299-301. PubMed ID: 7005542
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The prevalence of folP1 mutations associated with clinical resistance to dapsone, in Mycobacterium leprae isolates from South Korea.
    Lee SB; Kim SK; Kang TJ; Chae GT; Chun JH; Shin HK; Kim JP; Ko YH; Kim NH
    Ann Trop Med Parasitol; 2001 Jun; 95(4):429-32. PubMed ID: 11454253
    [No Abstract]   [Full Text] [Related]  

  • 53. Single-dose treatment for paucibacillary leprosy; feasibility of long-term follow up.
    Ganapati R; Revankar CR; Pai VV; Kingsley S
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):308-9. PubMed ID: 10575413
    [No Abstract]   [Full Text] [Related]  

  • 54. Chemotherapy of leprosy for control programmes.
    World Health Organ Tech Rep Ser; 1982; 675():1-33. PubMed ID: 6806990
    [No Abstract]   [Full Text] [Related]  

  • 55. Single-dose treatment for paucibacillary leprosy; field implications.
    Revankar CR; Pai VV; Samy MS; Ganapati R
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):312-4. PubMed ID: 10575415
    [No Abstract]   [Full Text] [Related]  

  • 56. Treatment failure in leprosy.
    Levy L
    Int J Lepr Other Mycobact Dis; 1976; 44(1-2):177-82. PubMed ID: 776854
    [No Abstract]   [Full Text] [Related]  

  • 57. Dihydropteroate synthase mutations in the folP1 gene predict dapsone resistance in relapsed cases of leprosy.
    Cambau E; Carthagena L; Chauffour A; Ji B; Jarlier V
    Clin Infect Dis; 2006 Jan; 42(2):238-41. PubMed ID: 16355335
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Skin smear examination in relation to multidrug therapy campaigns.
    Bhatia VN
    Indian J Lepr; 1987; 59(1):75-9. PubMed ID: 3302062
    [No Abstract]   [Full Text] [Related]  

  • 59. An appraisal of medical research in the treatment and control of leprosy.
    Rees RJ
    Lepr India; 1982 Oct; 54(4):783-800. PubMed ID: 6763969
    [No Abstract]   [Full Text] [Related]  

  • 60. Viability and drug susceptibility testing of M. leprae using mouse footpad in 37 relapse cases of leprosy.
    Shetty VP; Wakade AV; Ghate S; Pai VV; Ganapati R; Antia NH
    Int J Lepr Other Mycobact Dis; 2003 Sep; 71(3):210-7. PubMed ID: 14608816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.